Search Results
Your search for ,WHo matches 20411 pages
Showing 1151 - 1200Chemotherapy Administration and Survival in Patients With Very Advanced Solid Tumors
In a study reported in JAMA Oncology, Canavan et al found no differences in overall survival between oncology practices that were more vs less likely to provide chemotherapy within the last 2 weeks of life to patients with very advanced solid tumors. As stated by the investigators, “ASCO and the...
New Study Highlights Benefits of Stepped Palliative Care in Advanced Lung Cancer
Researchers have shown the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings published by Temel et al in JAMA and simultaneously presented at the 2024 ASCO Annual Meeting (Abstract 12000). Background More intensive...
Stress Related to Residing in Violent Neighborhoods May Be Tied to Aggressive Lung Cancer in Black Men
Exposure to increased neighborhood violence may change the glucocorticoid receptor for the stress hormone cortisol and influence the aggressiveness of lung cancer, according to new findings presented by Heath et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Study Methods and...
Adjuvant Radiotherapy With 24 vs 6 Months of ADT in Prostate Cancer
In a component of the phase III RADICALS-HD trial reported in The Lancet, Parker et al found that metastasis-free survival was improved with the addition of 24 months vs 6 months of androgen-deprivation therapy (ADT) to adjuvant radiotherapy in prostate cancer. A second component of the trial, not...
Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010). Background Circulating...
Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma
A novel “armored” type of chimeric antigen receptor (CAR) T-cell therapy called huCART19-IL18 may prove to be effective in patients with non-Hodgkin lymphoma who do not respond to standard CAR T-cell therapy, according to recent findings from a phase I clinical trial presented by Svoboda et al at...
Risk Factors and Outcomes Among Women With Interval vs Screen-Detected Breast Cancer
In a Korean study reported in JAMA Network Open, Song et al identified risk factors for interval breast cancer vs screen-detected breast cancer and described mortality outcomes for women in the two categories. Study Details The retrospective cohort study used data from the Korean National Health...
Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).
Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were...
Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal ...
Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease
Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer...
Telehealth May Reduce Greenhouse Gas Emissions Associated With Cancer Care
Telemedicine visits for cancer care are not only more convenient and possibly easier to schedule than in-person appointments—they may also be better for the planet. These findings were presented by Andrew Hantel, MD, and colleagues at the 2024 ASCO Annual Meeting (Abstract 1522) and simultaneously...
Study Including Only Black Patients With Breast Cancer Compares Rates of Taxane-Induced Peripheral Neuropathy
New findings suggest that docetaxel may be considered the preferred treatment over paclitaxel for Black patients with early-stage breast cancer. While the EAZ171 trial focused specifically on Black people, the results highlight the need to personalize therapy to minimize toxicity. Importantly, this ...
Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment
Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).
Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay ...
Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly...
Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse
Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free...
Neoadjuvant Immunotherapy Combination Improves Outcomes in Patients With Melanoma
Neoadjuvant immunotherapy given for stage III melanoma—followed by adjuvant therapy only if there is not a deep response to treatment—may produce better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. These results from the NADINA trial were presented ...
Advanced Ovarian Cancer: Can Lymphadenectomy Be Avoided for Some Patients?
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented by Classe et al at the 2024 ASCO Annual Meeting...
Osimertinib for Patients With Locally Advanced EGFR-Mutated NSCLC: A New Standard of Care?
Osimertinib improved progression-free survival in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) that has been treated with chemoradiotherapy—and may be a new standard of care for this population, according to research presented by Suresh Ramalingam, MD, FACP,...
Consolidation Therapy With Durvalumab for Limited-Stage SCLC
Results from an interim analysis of the phase III ADRIATIC study demonstrated that consolidation therapy after chemoradiotherapy with durvalumab extends survival in patients with limited-stage small-cell lung cancer (SCLC) compared to the current standard-of-care treatment of chemoradiotherapy...
T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy
Fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor (HR)-positive, HER2-low or -ultralow metastatic breast cancer that progressed following endocrine therapy, according to findings from the phase III DESTINY-Breast06 trial. The research was presented by...
Perioperative Chemotherapy vs Neoadjuvant Chemoradiation in Esophageal Cancer
For patients with locally advanced esophageal adenocarcinoma that can be treated with surgery, chemotherapy administered before and after surgery improved survival compared to chemoradiotherapy before surgery. The research was presented by Hoeppner et al at the 2024 ASCO Annual Meeting (Abstract...
Adding Belantamab Mafodotin to Doublet May Slow Disease Progression or Death in Relapsed or Refractory Myeloma
According to results from the phase III DREAMM-8 trial, adding belantamab mafodotin-blmf to pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma was more effective at slowing disease progression or death compared to the current standard-of-care triplet,...
Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial
Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in...
Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data
Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).
Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).
Antibody-Drug Conjugate Plus Checkpoint Inhibitor for PD-L1–Positive, HR-Positive/HER2-Negative Breast Cancer
In patients with metastatic hormone receptor (HR)-positive/HER2-negative breast cancer unselected by PD-L1 status, adding the immune checkpoint inhibitor pembrolizumab to the antibody-drug conjugate sacituzumab govitecan-hziy resulted in a 1.9-month improvement in median progression-free survival...
Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates
The novel anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) without a subsequent stem cell transplant, according to results from the phase...
American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration
The American Cancer Society (ACS) and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support,...
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
On May 30, the U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a...
Lorlatinib vs Crizotinib for Advanced ALK-Positive NSCLC: Extended CROWN Follow-up
The CROWN study (ClinicalTrials.gov identifier NCT03052608) of lorlatinib, a brain-penetrant, third-generation ALK tyrosine kinase inhibitor, vs crizotinib, an inhibitor of receptor tyrosine kinases (including ALK), in the first-line treatment of patients with advanced ALK-positive non–small cell...
Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?
A novel combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in previously treated patients with metastatic colorectal cancer compared to the targeted therapy regorafenib alone. These findings will be presented by Wainberg et al at the 2024 ASCO...
Differences in Prostate Cancer Genomics Among U.S. Veterans
Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by Valle et al at the 2024 ASCO Annual Meeting (Abstract 5017). The research could translate into...
A Father’s Advice Plus a Desire to Help Spur a Career in Oncology and a Leadership Role in African Cancer Care
Miriam Mutebi, MD, MSc, FACS, was born and reared in the outskirts of Nairobi, Kenya. “The suburb I grew up in (Langata), has seen a lot of development over the past couple of decades. When I was a child, it was a smaller community, where you would go and play at somebody else’s house and have...
For an International Expert in Gynecologic Cancer, Being Reared by Educators Who Stressed Knowledge and Service Was Key
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to her current position as Founding Dean and Chief Executive Officer of the Alice L. Walton School of Medicine, Bentonville, Arkansas. Raised by...
Motivated by His Mother’s Brain Cancer and His Own Life-Threatening Disease, a Young Physician Works to ‘Pay Back the Universe’
Like many young boys, David Fajgenbaum, MD, MBA, MSc, loved sports and dreamed about playing college football. He attained that dream, but along the way, family tragedy and a personal battle with a life-threatening disease reshaped his worldview and accelerated his ambitions as a...
Immigrant Reared During the Lebanese Civil War by Parents Who Valued Education Becomes a Leader in Genitourinary Oncology
Genitourinary cancer expert Toni K. Choueiri, MD, FASCO, was born in 1975 in Beirut, Lebanon, the year a devastating civil war erupted, lasted for 15 years, and cost the lives of some 150,000 individuals and also led to the exodus of almost 1 million people from Lebanon. “People with the financial...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
The National Cancer Act of 1971 Inspired a Career in Service to and Advocacy for Patients With Cancer
ASCO President for the 2024–2025 term, Robin Zon, MD, FACP, FASCO, was born and reared in Cheektowaga, a town in the western part of New York. “Cheektowaga is the Native American name for ‘land of the crabapple tree.’ Western New York was first settled by one of seven tribes belonging to the...
A Mother’s Encouragement and a Husband-Wife Doctor Team Set the Stage for a Career in Hematologic Oncology
Lymphoma expert Jane N. Winter, MD, grew up on the south shore of Long Island in New York. “My dad sold cars in my great uncle’s dealership after a failed foray into business after World War II. My mom graduated high school at 16 to go to work to help support her family. When my younger brother...
A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
FDA’s Crowdsourcing Initiative to Benefit Patient-Centric Clinical Trial Innovation
The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) recently announced a new initiative called “Project 5 in 5.” Project 5 in 5 is a crowdsourcing initiative to ultimately identify five clinically relevant questions that can be answered through use of pragmatic...
Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference
ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...
Cancer Incidence, Curative Treatment, and Overall Survival in the English Prison Population
In a study reported in The Lancet Oncology, Lüchtenborg et al found that the incidence of cancer increased in the prison population in England between 1998 and 2017; those with cancer were less likely to receive curative treatment and had poorer overall survival vs patients with cancer in the...
Advanced Ovarian Cancer: Adding Ruxolitinib to Front-Line Neoadjuvant Chemotherapy Plus Interval Debulking Surgery
In a phase I/II NRG Oncology Group study reported in the Journal of Clinical Oncology, Landen et al found that the addition of ruxolitinib to front-line paclitaxel/carboplatin neoadjuvant chemotherapy and interval debulking surgery improved progression-free survival in patients with stage III to IV ...
FDA Grants Accelerated Approval to Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Other Solid Tumors
On May 29, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the RET inhibitor selpercatinib (Retevmo) for pediatric patients aged 2 years and older with the following: Advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved...
Are Tattoos Linked to a Heightened Risk of Lymphoma?
Tattoos may be a risk factor in the development of lymphoma, according to a recent study published by Nielsen et al in eClinicalMedicine. Background A majority of individuals receive their first tattoos at a young age, exposing them to tattoo ink for a larger portion of their lives. The long-term...
ASTRO Releases Updated Clinical Guidelines on Radiation Therapy for Patients With Bone Metastases
The American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology....
